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The role of the vascular microenvironment in the pathogenesis Systemic Sclerosis (SSc) is appreciated clinically as Raynaud’s
syndrome with capillary nail bed change. This manifestation of vasculopathy is used diagnostically in both limited and diﬀuse
cutaneous subsets of SSc, and is thought to precede ﬁbrosis. The degree of subsequent ﬁbrosis may also be determined by the
vascular microenvironment. This paper describes why the vascular microenvironment might determine the degree of end-organ
damage that occurs in SSc, with a focus on vascular cell senescence, endothelial progenitor cells (EPC) including multipotential
mesenchymalstemcells(MSC),pericytes,andangiogenicmonocytes.AnexplanationoftheroleofEPC,pericytes,andangiogenic
monocytes is important to an understanding of SSc pathogenesis. An evolving understanding of the vascular microenvironment
in SSc may allow directed treatment.
1.Introduction
Systemic sclerosis (SSc, scleroderma) is an autoimmune
diseasecharacterizedearlyintheprocessbyvasculopathyand
subsequentlybyvaryingdegreesofﬁbrosisinskin,lungs,and
other tissues. The presence of vasculopathy is the hallmark of
this condition, represented clinically as Raynaud’s syndrome
which occurs almost universally in both the limited and
diﬀuse cutaneous subsets of this disease. Calcinosis and
telangiectasias are also features of SSc vascular damage.
Vasculopathy possibly results from abnormal vasoreactivity,
hypoxia, and/or direct damage of vascular and perivascular
cells [1]. Perivascular inﬂammatory inﬁltrates and neoan-
giogenesis ensues resulting in varying degrees of ﬁbrosis in
the skin and internal organs [2]. This paper describes why
details of the vascular microenvironment might determine
the degree of end-organ damage that occurs in SSc, with a
focusonvascularcellsenescence,endothelialprogenitorcells
(EPC) including mesenchymal stem cells (MSC), pericytes,
and angiogenic monocytes. An explanation of the role of
EPC, pericytes, and angiogenic monocytes is important to
understanding SSc pathogenesis.
SSc is thought to be a genetically complex disease, inﬂu-
enced by multiple genes, with a substantial environmental
component [3]. Nonetheless, SSc occurs signiﬁcantly more
frequently in families with scleroderma (1.6%) than in the
general population (0.026%) [4]. Genome-wide association
studies have found a strong association with the HLA II
regiononchromosome6,andnon-HLAcandidategenesthat
regulate interferon production, such as interferon regulatory
factor 5 (IRF 5) as well as genes that regulate immunological
responses, such as signal transducer and activator 4 (STAT 4)
[5, 6]. There are also multiple HLA class II associations
with autoantibody markers and subphenotypes [7]. As such,
systemic sclerosis is an autoimmune disease; however the
inherited eﬀects of vasculopathy and ﬁbrosis remain to be
determined. Our previous work showed that vasculopathy
imparts a greater relative risk to family members than
does autoimmune inﬂammatory conditions or ﬁbrotic lung
disease [8].2 International Journal of Rheumatology
2. VascularSenescence
The microvascular environment in SSc has a reduced
density and disorganized structure [9]. Irrespective of the
subset of SSc, perivesicular inﬂammatory inﬁltrates result in
endothelial derangement in lesioned as well as perilesional
tissue [10, 11]. These perivascular changes precede the
excessive accumulation of extracellular matrix components,
and ﬁbrosis may represent a default pathway from vascular
failure [12, 13]. The histopathological hallmark in SSc is a
result of endothelium activation with cell adhesion molecule
expression, inﬂammatory cell recruitment, intimal prolifer-
ation, and adventitial ﬁbrosis, which results in apoptosis of
endothelial cells [13, 14]. Despite the ensuing severe tissue
hypoxia, proper adapted angiogenesis does not occur in SSc
[2].
Vascular cells normally have a ﬁnite lifespan which is
determined in part by telomere length and/or telomerase
activity [15]. Telomerase is a reverse transcriptase which
helps maintain telomere length, thereby preventing cell
senescence and protecting chromosomes from aberration.
Althoughtelomeraseactivityisincreasedinmanyconnective
tissue diseases, it is decreased in systemic sclerosis (SSc),
perhaps due to gene polymorphism [16, 17].
T h e r eh a v eb e e nc o n t r a s t i n gr e p o r t so ft e l o m e r el e n g t h
in SSc. Artlett and colleagues reported a decrease telom-
ere length in a combined cohort of limited SSc (lSSc)
and diﬀuse SSc (dSSc) whereas MacIntyre and colleagues
reported increased telomere length and lack of age-related
telomere erosion in lSSc [18, 19]. In a pilot study, we used
a monochrome multiplex quantitative PCR (MMQPCR)
method to evaluate the relative telomere lengths (t/s ratios)
in DNA samples of 6 lSSc (1 male; 5 females) and 6 dSSc (3
males; 3 females) aging 40–60, and 50 healthy controls (HC)
aging 37–60 [20]. Two factors were statistically associated
(P value <. 001) to t/s: age and diagnosis (Figure 1).
Not correcting for age, the average length measure was
1.2 for normals, 1.15 for dSSc and 0.96 for lSSc patients
(Figure 2). Gender was not statistically associated with t/s.
Telomere length, which is shorter in SSc patients than in
normal HC, is possibly a risk factor for vasculopathy. While
the appearance of vasculopathy does not vary per subtype
of SSc, the eﬀect of telomere length on the ﬁbrocyte or
myoﬁbroblast may be diﬀerent in lSSc and dSSc, possibly
contributing to diﬀerences in disease manifestations. The
reduced telomere length in the endothelial cell likely results
in chronic underperfusion and ischemia in the skin and
internal organs in both lSSc and dSSc. However, if ﬁbrosis is
the default pathway of insuﬃcient angiogenic response, the
subsequent reduced lifespan of the ﬁbrocyte (determined by
telomere length) may be protective in the lSSc subtype.
3. Endothelial ProgenitorCellsandPericytes
The vascular network is a dynamic organ with an estimated
surface area of >1000m2 [21]. Neovascularization is a
complex process that requires both the mobilization of
cells derived from the bone marrow, named endothelial
progenitor cells (EPCs), and proliferation and diﬀerentiation
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Figure 1: Telomere length of females and males with Systemic
Sclerosis (SSc) compared to Healthy Controls.
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Figure 2: Telomere length of Healthy Controls, diﬀuse cutaneous
Systemic Sclerosis, limited cutaneous Systemic Sclerosis.
of resident cells, known as pericytes, to migrate to the correct
location and assemble into vascular structures [22].
New vessels are produced by a combination of angiogen-
esis and vasculogenesis. In angiogenesis, fully diﬀerentiated
endothelial cells arise from pre-existing vessels whereas
vasculogenesis describes the formation of new vessels by
circulating EPC which act to replenish damaged or senescent
blood vessels [14]. This process requires dynamic and
temporally regulated interactions between endothelial cells,
soluble proangiogenic and antiangiogenic growth factors,
and extracellular matrix molecules [23].
Primary contact between endothelial cells and mural
cells (pericyte and vascular smooth muscle cells) is centralInternational Journal of Rheumatology 3
to the regulation of vascular formation in angiogenesis
[24]. Recently formed endothelial tubes are initially unstable
and become stabilized through the formation of a peri-
vascular matrix and the connection with pericytes [25].
Pericytes are embedded within the endothelial basement
membraneandarefoundprimarilyaroundbloodcapillaries,
precapillary arterioles, postcapillary venules, and collecting
venules [26]. They are arranged to facilitate and assimilate
cellcommunication.WithparticularinteresttoSSc,pericytes
may play a role in ectopic calciﬁcation and are able to
transdiﬀerentiate into ﬁbroblast-like cells if they escape from
the capillary basement membrane [27]. Furthermore, mural
cell defects are reported in other diseases characterized by
telangiectasias [28] .T h ep e r i c y t er o l ea sap e r i v a s i c u l a r
mesenchymal stem cell with macrophage-like properties has
not been welldeﬁned in SSc, but is intriguing.
The pericyte is critical for maintenance of vascular
stability. Its ability to perform this function is corre-
lated with marker expression and the microenvironment
of the endothelial-pericyte contact. Most likely, speciﬁc
intercellular signals mediated by ligand-receptor systems
are required for endothelial and pericyte vascular stability
[24]. Numerous studies demonstrate the critical importance
of transforming growth factor- (TGF)-beta signaling for
vascular development and function [24]. TGF-beta has
context-dependent eﬀects on endothelial cells; proliferation
is mediated by signaling through ALK/Smad1/5 and diﬀer-
entiation is mediated by ALK Smad2/3 [29]. TGF-beta/Smad
signaling has been suggested to play a key role in the
pathogenesis of SSc [30].
In postnatal vasculogenesis, pericytes develop from
tissue-derived stem cells and/or peripheral EPC [31]. Iden-
tiﬁcation and quantiﬁcation of EPC population in SSc
has been challenging and has resulted in consensus rec-
ommendations to help unify EPC research [14]. Research
by Avouac and colleagues, using an accurate, reliable, and
reproducible method of EPC quantiﬁcation, supports that
SSc is associated with EPC mobilization, but in active or
severe stages, EPC may be recruited to injured sites and thus
decrease in the circulation [9].
Multipotential mesenchymal stem cells (MSCs) might be
a source of EPC in vasculogenesis [2]. MSCs show normal
functional properties and a normal pattern of biological
markers, but the angiogenic potential of these endothelial-
like MSCs is reduced [32]. Cipriani and colleagues showed
that when MSC from SSc patients are seeded on Matrigel,
they have a reduced ability to form capillary-like structures
and give rise to incomplete endothelial networks, even after
vascular endothelial growth factor (VEGF) and stromal-
derived factor (SDF-1) stimulation [23, 32].
VEGF is an important angiogenic peptide with speciﬁc
proliferative, diﬀerentiation, and mobilization eﬀects on
EPCs, and is known to be upregulated in SSc, especially
in advanced disease [33]. VEGF gene expression is also
regulated by growth factors (such as TGF-beta) and other
proinﬂammatory cytokines. The platelet-derived growth
factor (PDGF) family is essential to vascular remodeling
and maturation [34]. In a study of 62 SSc patients, EPCs
were signiﬁcantly increased in patients with early-stage SSc
disease, but not in those with late disease irrespective of
diagnosis subtype, and there was no correlation between the
number of circulating EPCs and VEGF [24]. Bone marrow
biopsy samples from 14 of these SSc patients (3 early limited
SSc, 4 with late limited SSc, 4 with early diﬀuse SSC, and 3
with late SSc) showed fewer and functionally impaired EPCs
in all patients [33]. Another study showed that the subset of
SSc patients with digital lesions and high severity scores had
low EPC counts [35]. It is possible that bone marrow from
SSc patients cannot satisfy the continuous and prolonged
demand for EPCs, despite the target organ increase in VEGF
[33].
The role of target organ microvascular environment
(pericytes and endothelial cells), which is producing TGF-
beta, VEGF, and PDGF, on SSc pathogenesis is less clear.
TGF-beta can be either pro- or antiangiogenic based on its
concentration [36]. The elevated total number and activated
state of circulating endothelial cells (CECs), suggest vascular
damage and endothelial activation in SSc patients regardless
of subtype correlates to disease activity [37]. Thus, vascular
damage may drive the disease. It is also known that TGF-beta
and PDGF from this microvasculature cooperate in inducing
the activation of ﬁbroblasts and their diﬀerentiation into
myoﬁbroblasts in SSc patients [38]. Thus, understanding
the microvascular environment of target organs in SSc is of
primary importance.
4. Angiogenic Monocytes
It is suggested that the major contribution of the bone
marrow to angiogenic processes may come from progenitors
of the periendothelial vascular mural cells [39]. Endothe-
lial diﬀerentiation of monocyte-derived multipotential cells
(MOMCs) can occur with angiogenic stimuli and result
in the formation of mature endothelial cell tubules in
Matrigelcultures[40].Pericytesestablishmorphologicinter-
actions with transmigrating leukocytes, mainly monocytes
(macrophages) [31]. During angiogenesis, macrophages
contribute to the dissociation and detachment of pericytes
from the endothelial cell. Pericytes can act as antigen-
presenting cells and can behave as macrophages; they also
can show plasticity with potential to become myoﬁbroblasts
[31]. Thus, understanding the role of the interaction of
circulating angiogenic monocyte and resident pericyte in SSc
microvasculature has important implications. It is possible
that this interaction is of primary importance for linking
the inﬂammatory aspect of the disease to the vascular
abnormalities.
Stromal cell-derived factor-1 (SDF-1) and its receptor
(CXCR4) system is a component of the microvascular
environment which is extremely important for new vessel
formation. SDF-1 released by endothelial cells creates a
gradient dictating directional response of endothelial cells
expressing CXCR4 [41]. Skin biopsies in early disease of
both SSc subtypes show a strong positive pattern of SDF-
1 and its receptor CXCR4 in the endothelial cells and
pericytesofmicrovessels,attestingtoanattemptedreparative
process [42]. Of interest, in diﬀuse SSc, these skin biopsies4 International Journal of Rheumatology
also showed dense mononuclear cells in the perivascular
inﬁltrate, possibly suggesting a role of the monocytes in
a more ﬁbrotic phenotype. The staining for CXCR4 was
weak in the late (sclerotic or atrophic) phases in both SSc
subsets [42]. Another study of 40 SSc patients demonstrated
higher serum levels of VEGF, PDGF, and increased con-
centration of SDF-1, particularly in the diﬀuse subset. In
this same study population circulating CXCR4+ circulating
progenitor cells coexpressing monocytic and endothelial
cells positively correlated to the severity score, modiﬁed
Rodnan skin score, and pulmonary involvement [43]. Taken
in sum, these results suggest that overall disease activity
correlates to the markers of activity in the microvascular
environment.
It has recently been suggested that the actual angiogenic
cell type recruited to the site of tissue injury and incor-
porated into a newly formed vessel is a monocyte [44].
Activated circulating monocytes have also been reported
in SSc patients, supporting a potential role of these cells
in disease pathogenesis [45]. Gene expression proﬁling of
peripheral blood monocytes from SSc patients suggest that
type I interferon may play a key role in the activation of
monocytes in this disease [46]. If during the course of
the disease, the mechanism of angiogenesis is impaired,
the proangiogenic factors in the microvascular environment
may serve to recruit proangiogenic monocytes which, with
pericytes,resultinoveractivityofamyoﬁbroblastphenotype.
In a preliminary study, there were no signiﬁcant diﬀerences
in the expression of circulating monocyte surface molecules
involved with cell transformation, function, or migration
presumed to give rise to ﬁbrocytes, in 8 patients with limited
SSc [47]. It is possible that the role of the angiogenic
monocytemaybegreaterinthediﬀusesubsetofSScandhave
prognostic implications.
5. Implicationsof the Vascular
Microenvironment on Treatment
An evolving understanding of the vascular microenviron-
ment in SSc may allow directed treatment. Therapeutics
that modulate the phenotype of reparative cells can oﬀer
new opportunities for SSc treatment [48]. In particular,
multipotential MSCs have attracted interest because of low
acute toxicity and their availability [49]. The potential of
human MOMCs which can proliferate and diﬀerentiate
alongtheendotheliallineageinaspeciﬁcpermissiveenviron-
ment also may represent an autologous transplantable cell
source for therapeutic neovasculogenesis [40]. In early SSc,
prevention of vascular senescence may be most important.
N-acetyl-cysteine (NAC), a chemopreventive antiangiogenic
and antiapoptotic drug has been suggested to modulate
parameters associated with endothelial cell aging [50]. Pilot
data suggests that the statin class of medications may be
beneﬁcial in treating vascular manifestations of SSc, through
an increase in angiogenic factors and reduction of vascular
endothelial activation/injury markers (P< . 01 for all
comparisons) [51]. However, this treatment did not correct
the defect in EPC recruitment. Cyclophosphamide, which
remainsthecurrentgoldstandardfortreatmentofinterstitial
lung disease, is known to mobilize EPC [52]. Nutraceutical-
based mobilization of EPC is an area of interest in the
biomedical ﬁeld, and has not yet been reported in SSc [53].
For the ﬁbrotic aspect of SSc, the small molecule
tyrosine kinase inhibitor imatinib and related drugs, such
as dasatinib and nilotinib, which simultaneously target two
of the major proﬁbrotic pathways, TGF-beta- and PDGF-
signaling are being studied [54]. The eﬀect of these drugs
on the microvascular environment, and their eﬃcacy and
tolerability in SSc patients are not yet known. Other anti-
TGF-beta therapies are also in development and may have
a major impact in systemic sclerosis. However, considerable
concern regarding safety is needed given its pro- and
antiangiogenic eﬀects at diﬀerent concentrations [55]. IFN
inhibitors are also under investigation for treatment of SSc,
though modulation of interferon may be most eﬀective in
the diﬀuse subset, in which there is a higher perivascular
monocyte inﬁltrate [56]. Speciﬁcally, therapies that inhibit
transdiﬀerentiation of other cell types, such as pericytes and
angiogenic monocytes into ﬁbroblasts and myoﬁbroblasts
hold promise [57].
6. Conclusion
A predisposition to vascular senescence is probable in SSc
and the pathogenesis may arise from a subsequent defect
in vasculogenesis (possibly due to abnormal bone marrow
function) and/or angiogenesis (perhaps due to pericyte and
angiogenic monocytes) followed by overactivity of activated
ﬁbroblasts and myoﬁbroblasts. Understanding the role of the
vascularmicroenvironmentwillbecriticaltodevelopmentof
directed therapeutics.
Early SSc may be most amenable to treatments that
decrease vascular senescence and increase EPC mobiliza-
tion. Surprisingly, diﬀuse cutaneous SSc may be more
responsive to therapeutics, which modulate pericyte and
angiogenic monocyte diﬀerentiation into activated ﬁbrob-
lasts and myoﬁbroblasts. The diﬃculty with therapeutics
which modulate growth factor and chemokines is that
locally varying levels of these substances are necessary for
regulation of migration, proliferation, cell-cell interactions,
diﬀerentiation, and extracellular matrix deposition [31].
Nonetheless, an improved understanding of the principle
regulatory mechanisms of angiogenesis in SSc has profound
potential therapeutic value. It is exciting to think that
through understanding of the microvascular environment in
SSc, that subsequent restoration of proper angiogenesis in
SSc could limit ﬁbrotic damage.
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